Coram is one of the country’s largest providers of comprehensive infusion services, as it serves more than 20,000 patients each month. By acquiring Coram and its national network of locations, CVS is aiming to broaden its specialty pharmacy offerings and make infusion treatments more cost-effective in the home or ambulatory settings, according to the news release.
Jon Roberts, president of CVS Caremark pharmacy services, said infusion will be a valuable component of the company’s specialty pharmacy offering going forward, according to the release.
Coram is expected to generate approximately $1.4 billion in revenues during the first 12 months following the close of the deal.
More Articles on CVS and Healthcare:
CVS Prescription Rewards Program Requires Patients to Sign Away HIPAA Rights
CVS Caremark’s MinuteClinics Blaze Trail for Other Retail Chains
CVS to Pay $11M to Settle Record-Keeping Violations
